Members Login
Channels
Special Offers & Promotions
BioTek Receives Frost & Sullivan Award
BioTek Instruments, Inc., proudly announces
that they are the recipient of the Frost Sullivan 2011 North American New
Product Innovation Award for Workflow Solutions in Life Sciences. Independent
analysis by Frost & Sullivan research teams determined that BioTek excelled
in its commitment to improving technology and streamlining workflows relative
to other companies in their business category. This focus has resulted in the
launch of over 20 new BioTek products in the market over the past four years.
The report cites BioTek's reputation for high-quality, cutting-edge microplate instrumentation, and best-in-class customer support. Two recent BioTek microplate instruments were highlighted: SynergyTM Hybrid Multi-Mode Microplate Readers, and the EL406TM Combination Washer Dispenser. Both combine multiple technologies in one unit, thus eliminating limitations associated with choosing one technology, and thus enhancing assay flexibility. Synergy H1 and Synergy H4 combine filter-based and monochromator-based optics in one microplate reader for increased assay flexibility and high performance. EL406 combines microplate washing with peristaltic and microprocessor-controlled syringe pumps for optimized liquid handling processes.
BioTek's Application Laboratory scientists partner with many diverse assay reagent companies and also maintain close relationships with customers to validate methods, fulfill unmet needs and solve challenges in the marketplace. Additionally, BioTek maintains strong quality practices, and measures customer pre-sale and post-sale satisfaction regularly to ensure that they are meeting or exceeding customer expectations.
"Ultimately, Frost & Sullivan is of the opinion that these practices result in a product line that boasts flexibility, automation of traditionally manual steps, technology integration, speed, and tremendous value for the price," noted Christi Bird, Industry Analyst at Frost & Sullivan. "Additionally, BioTek's scientific expertise and relationship building fosters new ideas, while its dedicated focus allows it to quickly act on ideas and turn them into reality."
Peter Weith, BioTek Vice President of Marketing, Sales and Service added, "We are humbled to be recognized by Frost & Sullivan for our efforts, and we remain committed to setting the bar for flexibility, ease-of-use and value in microplate technologies, and eliminating workflow challenges for our customers."
Frost & Sullivan, the growth partnership company, is a global market analysis and solution leader that identifies companies demonstrating best practices in a variety of regional and global markets. These Awards commend superior planning and execution of product launches, strategic alliances, distribution strategies, technological innovations, mergers and acquisitions, and initial public offerings. A host of other crucial marketing factors, such as leadership, strategy, service, innovation, integration, and development, are also recognized.
BioTek Instruments, Inc., headquartered in Winooski, VT, USA, is a worldwide leader in the design, manufacture, and sale of microplate instrumentation and software. BioTek instrumentation is used to aid in the advancement of life science research, facilitate the drug discovery process and to enable cost-effective quantification of disease relevant molecules in the clinic.
The report cites BioTek's reputation for high-quality, cutting-edge microplate instrumentation, and best-in-class customer support. Two recent BioTek microplate instruments were highlighted: SynergyTM Hybrid Multi-Mode Microplate Readers, and the EL406TM Combination Washer Dispenser. Both combine multiple technologies in one unit, thus eliminating limitations associated with choosing one technology, and thus enhancing assay flexibility. Synergy H1 and Synergy H4 combine filter-based and monochromator-based optics in one microplate reader for increased assay flexibility and high performance. EL406 combines microplate washing with peristaltic and microprocessor-controlled syringe pumps for optimized liquid handling processes.
BioTek's Application Laboratory scientists partner with many diverse assay reagent companies and also maintain close relationships with customers to validate methods, fulfill unmet needs and solve challenges in the marketplace. Additionally, BioTek maintains strong quality practices, and measures customer pre-sale and post-sale satisfaction regularly to ensure that they are meeting or exceeding customer expectations.
"Ultimately, Frost & Sullivan is of the opinion that these practices result in a product line that boasts flexibility, automation of traditionally manual steps, technology integration, speed, and tremendous value for the price," noted Christi Bird, Industry Analyst at Frost & Sullivan. "Additionally, BioTek's scientific expertise and relationship building fosters new ideas, while its dedicated focus allows it to quickly act on ideas and turn them into reality."
Peter Weith, BioTek Vice President of Marketing, Sales and Service added, "We are humbled to be recognized by Frost & Sullivan for our efforts, and we remain committed to setting the bar for flexibility, ease-of-use and value in microplate technologies, and eliminating workflow challenges for our customers."
Frost & Sullivan, the growth partnership company, is a global market analysis and solution leader that identifies companies demonstrating best practices in a variety of regional and global markets. These Awards commend superior planning and execution of product launches, strategic alliances, distribution strategies, technological innovations, mergers and acquisitions, and initial public offerings. A host of other crucial marketing factors, such as leadership, strategy, service, innovation, integration, and development, are also recognized.
BioTek Instruments, Inc., headquartered in Winooski, VT, USA, is a worldwide leader in the design, manufacture, and sale of microplate instrumentation and software. BioTek instrumentation is used to aid in the advancement of life science research, facilitate the drug discovery process and to enable cost-effective quantification of disease relevant molecules in the clinic.
Media Partners